Skip to main content
OpenTrials
Completed

NCT Number: NCT06919276

Nicotine and Cannabis Vape Labeling Experiment - Spring 2025

This study assesses how the ways in which nicotine and cannabis vaping devices are labeled impact use susceptibility, anticipated effects, and health harm.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vaping Adolescent Behavior Cannabis Chemically-Induced Disorders Electronic Cigarette Use Marijuana Abuse Mental Disorders Nicotine Smoking Substance-Related Disorders

Age range

11 year–19 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Southern California

Los Angeles, California, 90032, United States

About this study

The primary objectives of the study: (1) Determine whether different device labels with the contained substance (nicotine or cannabis) affect adolescent use susceptibility, anticipated effects or impairment, and perceived health harms; (2) Determine whether device color/product flavor differentially impact the study outcomes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must be enrolled in a partnering high school.

Exclusion criteria

  • Participants who cannot independently understand study consent and the study surveys are ineligible.

Treatment and study plan

Vaping Device Labeling

Other

Participants will view one vape image (experimental stimulus) and are randomized to a label presented and the color/flavor of the vaping device presented.

The label conditions are:

  • plain (i.e., no labeling on device)
  • "contains THC"
  • "contains 80% THC"
  • "contains 80% THC - HIGH POTENCY"
  • "contains nicotine"
  • "contains 5% nicotine"
  • "contains 5% nicotine - HIGH STRENGTH" The color/flavor conditions are: mint/mint, white/original, blue/blueberry.

Primary outcomes

  1. Use Intention Susceptibility

    Time frame: 5 minutes

    This 3-item self-report measure assesses participant interest in trying the vaping device in the future. A 4-level Likert scale is used: definitely not, probably not, probably yes, definitely yes.

  2. Perceived Health Harms

    Time frame: 5 minutes

    This 2-item self-report measure assesses participant perception of health harms and risks associated with using the vaping product. A 4-level Likert scale is used: definitely not, probably not, probably yes, definitely yes.

  3. Anticipated Subjective Effects

    Time frame: 5 minutes

    This 9-item self-report measure assesses anticipated subjective effects from using the vaping device. Participants will select all that apply.

  4. Anticipated Impairment/Enhancement

    Time frame: 5 minutes

    This 4-item self-report measure assesses participant anticipated enhancement or impairment effects on completing different activities due to using the vaping product. A 5-level Likert scale is used: definitely make it harder, probably make it harder, no effect, probably make it easier, definitely make it easier.

Sponsors and collaborators

Lead sponsor

University of Southern California

Other

Collaborators

  • National Cancer Institute (NCI)
  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Longitudinal Patterns of Non-Combustible Tobacco Product Use in Adolescents (EPIC) / Assessing Development Patterns of Vaping, Alcohol, Nicotine, and Cannabis Use and Emotional Well-being (ADVANCE)

Acronym: EPIC/ADVANCE

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 9, 2025
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.